In India, diabetes is an issue that has been growing rapidly as a health issue. As outlined by the International Diabetes Federation (IDF), there are more than 77 million people in India who live with diabetes at the moment, and the number will exceed 101 million by 2030. The immediate increase in cases has led to an urgent need for effective, affordable, and reliable anti-diabetic products in the PCD company portfolios.
This increasing demand is also becoming an opportunity for pharma entrepreneurs, where they could join diabetic PCD firms on franchises and develop sustainable businesses. But why is there this rush, and what does it imply for the pharmaceutical industry? Let's explore.
Urbanization has brought comfort in the form of unhealthy habits. Lack of exercise and eating fast and low-energy foods are the principal causes of type 2 diabetes.
South Asians are genetically more susceptible to insulin resistance, and Indians are especially susceptible to the development of diabetes at a younger age than the Western population.
Stressful professions and disrupted diets and sleep have also increased the risk, particularly among the working-age group.
Diabetes is a chronic and lifelong condition, as opposed to many diseases. Patients use oral medications, insulin shots, test strips, and supportive treatment daily. This guarantees the products that are related to anti-diabetic maintenance in India.
The management of diabetes has become more affordable in Tier-2 and Tier-3 cities with government-provided programs such as Ayushman Bharat and an increase in the number of hospitals and clinics. This has diversified the market of diabetic PCD companies to franchise partners.
In the past, most of the population neglected the initial signs of diabetes. In the modern world, awareness campaigns and regular health check-ups have made patients more proactive regarding diagnosis and treatment; this is fueling steady medicine demand.
In addition to the allopathic products, Ayurvedic PCD franchise companies are also making an entry into the field with herbal formulations purported to control blood sugar naturally. Such a mix of modern and traditional medicine enhances the product line of pharma distributors.
PCD (Propaganda-Cum-Distribution) is now one of the best means of reaching patients in all quarters of the nation. Through the collaboration with reputable brands, franchisees can introduce the products of the PCD company that are related to anti-diabetics into local markets.
Monopoly rights: A variety of companies provide monopoly PCD pharma franchises that provide exclusive rights to distribute in a certain territory.
Low investment, high returns: The demand guarantees frequent sales and repeat orders.
Marketing assistance: It is easier to educate doctors and pharmacists with the help of visual aids, product samples, and digital tools.
Diversity of products: Franchise partners have an opportunity to sell tablets, capsules, injections, and herbal supplements under the same umbrella.
One of the key factors that has led to the increasing demand is that companies are able to fulfill it with proper manufacturing and distribution. Most diabetic care brands also use third-party manufacturing pharma companies to have the option of scalability without sacrificing quality.
Pros of Third-Party Manufacturing:
Both the companies and the franchise partners find it cost-effective.
Maintains the supply of medicines on time.
The safety of products produced under WHO-GMP and ISO-certified facilities ensures safety.
They guarantee the supply of necessary medicines in all cities and towns through franchise distributors to satisfy the rising patient needs.
Yes. Numerous ayurvedic PCD franchise companies are producing herbal products, which could aid in the regulation of blood sugar. Nevertheless, they should be used by the patients under the supervision of medical personnel.
It provides a monopoly to market anti-diabetic products within a region and enhances profitability for the distributor.
It enables businesses to expand swiftly and keep production quality at WHO-GMP and ISO standards to ensure patients never run out.
Yes. Patients need lifelong treatment, and the demand is constant, which makes it one of the most reliable business segments of pharma franchises.
Iscon Life Sciences Pvt. Ltd. is one of the most prominent pharmaceutical companies operating in the Indian market that focuses on the creation of cardiac diabetic PCD pharma franchise portfolios. We offer the best franchise partner to anyone who wishes to partner with diabetic PCD companies with WHO-GMP certified manufacturing, good marketing support, and a reputation for reliability.
Are you ready to grow into the most promising business in the pharma industry? Meet Iscon Life Sciences Pvt. Ltd. today and see what opportunities a franchise will offer in your area.
Your email address will not be published. Required fields are marked *
